CORT
Price
$70.86
Change
-$2.24 (-3.06%)
Updated
Jul 18 closing price
Capitalization
7.51B
10 days until earnings call
HNSBF
Price
$2.74
Change
-$0.26 (-8.67%)
Updated
Jul 17 closing price
Capitalization
236.87M
Interact to see
Advertisement

CORT vs HNSBF

Header iconCORT vs HNSBF Comparison
Open Charts CORT vs HNSBFBanner chart's image
Corcept Therapeutics
Price$70.86
Change-$2.24 (-3.06%)
Volume$563.1K
Capitalization7.51B
Hansa Medical AB
Price$2.74
Change-$0.26 (-8.67%)
Volume$7.12K
Capitalization236.87M
CORT vs HNSBF Comparison Chart in %
Loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HNSBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CORT vs. HNSBF commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and HNSBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (CORT: $70.86 vs. HNSBF: $2.74)
Brand notoriety: CORT and HNSBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 40% vs. HNSBF: 896%
Market capitalization -- CORT: $7.51B vs. HNSBF: $236.87M
CORT [@Biotechnology] is valued at $7.51B. HNSBF’s [@Biotechnology] market capitalization is $236.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 1 FA rating(s) are green whileHNSBF’s FA Score has 0 green FA rating(s).

  • CORT’s FA Score: 1 green, 4 red.
  • HNSBF’s FA Score: 0 green, 5 red.
According to our system of comparison, CORT is a better buy in the long-term than HNSBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 3 TA indicator(s) are bullish while HNSBF’s TA Score has 1 bullish TA indicator(s).

  • CORT’s TA Score: 3 bullish, 5 bearish.
  • HNSBF’s TA Score: 1 bullish, 4 bearish.
According to our system of comparison, both CORT and HNSBF are a bad buy in the short-term.

Price Growth

CORT (@Biotechnology) experienced а -1.42% price change this week, while HNSBF (@Biotechnology) price change was -8.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

CORT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($7.51B) has a higher market cap than HNSBF($237M). CORT YTD gains are higher at: 40.623 vs. HNSBF (-8.667). CORT has higher annual earnings (EBITDA): 112M vs. HNSBF (-523.23M). CORT has more cash in the bank: 323M vs. HNSBF (250M). CORT has less debt than HNSBF: CORT (6.84M) vs HNSBF (1.02B). CORT has higher revenues than HNSBF: CORT (685M) vs HNSBF (182M).
CORTHNSBFCORT / HNSBF
Capitalization7.51B237M3,170%
EBITDA112M-523.23M-21%
Gain YTD40.623-8.667-469%
P/E Ratio61.62N/A-
Revenue685M182M376%
Total Cash323M250M129%
Total Debt6.84M1.02B1%
FUNDAMENTALS RATINGS
CORT vs HNSBF: Fundamental Ratings
CORT
HNSBF
OUTLOOK RATING
1..100
850
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
43100
PRICE GROWTH RATING
1..100
4180
P/E GROWTH RATING
1..100
9100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HNSBF's Valuation (70) in the null industry is in the same range as CORT (83) in the Pharmaceuticals Other industry. This means that HNSBF’s stock grew similarly to CORT’s over the last 12 months.

CORT's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for HNSBF (100) in the null industry. This means that CORT’s stock grew somewhat faster than HNSBF’s over the last 12 months.

CORT's SMR Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for HNSBF (100) in the null industry. This means that CORT’s stock grew somewhat faster than HNSBF’s over the last 12 months.

CORT's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for HNSBF (80) in the null industry. This means that CORT’s stock grew somewhat faster than HNSBF’s over the last 12 months.

CORT's P/E Growth Rating (9) in the Pharmaceuticals Other industry is significantly better than the same rating for HNSBF (100) in the null industry. This means that CORT’s stock grew significantly faster than HNSBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTHNSBF
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
25%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
69%
N/A
Momentum
ODDS (%)
Bearish Trend 3 days ago
60%
Bearish Trend 3 days ago
18%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
25%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
24%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 3 days ago
25%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
42%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HNSBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PPI16.670.04
+0.22%
Astoria Real Asset ETF
SPMV48.18N/A
N/A
Invesco S&P 500 Minimum Variance ETF
CADJPY108.06-0.05
-0.05%
Canadian Dollar - Japan Yen
JETS24.99-0.11
-0.44%
US Global Jets ETF
PBDC34.85-0.19
-0.54%
Putnam BDC Income ETF

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with DNLI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
-3.06%
DNLI - CORT
40%
Loosely correlated
-3.65%
TENX - CORT
38%
Loosely correlated
+1.36%
ARCT - CORT
38%
Loosely correlated
-0.30%
HNSBF - CORT
38%
Loosely correlated
N/A
INSM - CORT
34%
Loosely correlated
N/A
More

HNSBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with CORT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then CORT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HNSBF
1D Price
Change %
HNSBF100%
N/A
CORT - HNSBF
38%
Loosely correlated
-3.06%
AVXL - HNSBF
36%
Loosely correlated
-0.72%
PMVP - HNSBF
31%
Poorly correlated
N/A
MLLCF - HNSBF
28%
Poorly correlated
N/A
ELTX - HNSBF
27%
Poorly correlated
N/A
More